{"id":"NCT05119855","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)","officialTitle":"A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-03-28","primaryCompletion":"2023-12-12","completion":"2023-12-12","firstPosted":"2021-11-15","resultsPosted":"2025-07-17","lastUpdate":"2025-07-17"},"enrollment":165,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Papillomavirus Infections","Coronavirus Disease (COVID-19)"],"interventions":[{"type":"BIOLOGICAL","name":"9vHPV Vaccine","otherNames":["V503","GARDASIL®9","SILGARD®9"]},{"type":"BIOLOGICAL","name":"mRNA-1273 Vaccine","otherNames":["SARS-CoV-2 Vaccine","Moderna COVID-19 Vaccine"]}],"arms":[{"label":"Concomitant Group","type":"EXPERIMENTAL"},{"label":"Non-concomitant Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus nonconcomitant administration of 9vHPV and mRNA-1273 vaccines in boys and girls 9 to 11 years of age.","primaryOutcome":{"measure":"Geometric Mean Titers of Anti-Human Papillomavirus Vaccine Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 (9vHPV)","timeFrame":"Up approximately 4 weeks post vaccination with 9vHPV Dose 2","effectByArm":[{"arm":"Concomitant Group","deltaMin":2198.5,"sd":null},{"arm":"Non-concomitant Group","deltaMin":1806.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":11},"locations":{"siteCount":38,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["https://www.merckclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":81},"commonTop":["Injection site pain","Headache","Fatigue","Injection site swelling","Lymphadenopathy"]}}